Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
B
099430
vs
K
KOSPI 200
Over the past 12 months, BioPlus Co Ltd has underperformed KOSPI 200, delivering a return of -41% compared to KOSPI 200's +108% growth.
Stocks Performance
099430 vs KOSPI 200
Performance Gap
099430 vs KOSPI 200
Performance By Year
099430 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
BioPlus Co Ltd
Glance View
BioPlus Co Ltd makes medical aesthetic products, especially hyaluronic acid-based dermal fillers used by doctors in cosmetic and reconstructive procedures. It also sells related beauty and skin-care products tied to the same anti-aging and tissue-care market. In simple terms, the company turns biomaterials into injectable products that help restore volume, smooth lines, and improve the look or feel of skin. Its main customers are clinics, hospitals, distributors, and other medical-aesthetics buyers, often through local and overseas sales channels. BioPlus makes money by selling finished products, and in some cases by supplying products through partners that market them under their own brands. That means its business depends on repeat orders from medical professionals and the regulatory approvals needed to sell these products in each market. What makes BioPlus different is that it sits in a niche part of healthcare where medicine and cosmetic treatment overlap. The company is not a drugmaker in the usual sense and not a general beauty company either; it sells physician-used products that are part of elective aesthetic care. That gives it a business model built around specialized formulations, medical distribution, and trusted use in clinics rather than mass retail.